论文部分内容阅读
R F P是目前常规使用的有效杀菌药。Languillon等的研究表明每天450mg和每月1200mg,BI下降的效果相同。细菌的被杀死和病人对死菌的清除是两回事。为了观察RFP每天600mg治疗9个月时BL下降的速度,以及Ⅱ型反应和肝炎的发生率是否高于每月一次给药,将88例新的MB病人随机分成两组,其年龄、性别均无统计上的差异。I组47例,男36,女11,给予DDS 100mg/日、B663 50mg/日、R F P 600mg/日, 9个月后,R F R改为600mg/月,疗程二年;I组41例,男36,女5,按WHO的MB方案。定期检查BI、肝功能等。二组治疗前B1分别为1.95和1.81,无明显差异。二年后BI分别为0.45和0.84,I组BI下降明显高于Ⅱ组.Ⅱ型反应和肝炎的发生率,在I组分别为12例(男8、女4)和3例(男2、女1),Ⅱ组分别为3例(男2、女1)和1例(男)。这与其它学者的研究不同,是因为没有可比性。在RFP每天给药组,虽然BI下降快,但I型反应和肝炎的发生率高,费用大,因此不宜推广。
R F P is an effective bactericide currently used routinely. Studies by Languillon et al. Show that 450 mg daily and 1200 mg monthly have the same effect of BI reduction. Bacteria are killed and the patient’s removal of dead bacteria are two different things. To observe the rate of BL decline at 600 mg daily for RFP at 9 months and whether the incidence of type II response and hepatitis was higher than monthly, 88 new MB patients were randomized into two groups, age and sex No statistical difference. 47 patients in group I, 36 males and 11 females, were given DDS 100mg / day, B663 50mg / day and RFP 600mg / day. After 9 months, the RFR was changed to 600mg / month for two years; Female 5, according to the WHO MB program. Regularly check BI, liver function and so on. B1 before treatment were 1.95 and 1.81, no significant difference. After two years, the BI was 0.45 and 0.84 respectively, and the decline of BI in group I was significantly higher than that in group B. The incidence of type II reaction and hepatitis in group I was 12 (male 8, female 4) and 3 (male 2, Female 1), and group Ⅱ was 3 (male 2, female 1) and 1 (male) respectively. This is different from the studies of other scholars because there is no comparability. In the RFP daily administration group, although the BI decreased rapidly, but the incidence of type I response and hepatitis, high cost, it is not appropriate to promote.